Int'l : +1(646) 600-5072 | query@kbvresearch.com
Published Date : 20-May-2024 |
Pages: 68 |
Formats: PDF |
The Japan Intracranial Aneurysm Market size is expected to reach $117.80 Million by 2030, rising at a market growth of 8.6% CAGR during the forecast period.
The intracranial aneurysm market in Japan is a critical aspect of the healthcare landscape, given the prevalence of this condition and its potentially life-threatening consequences. Japan has been experiencing a significant burden of intracranial aneurysms due to various factors such as an aging population, lifestyle changes, and improved diagnostic capabilities. As the population ages, the incidence of intracranial aneurysms tends to increase, necessitating effective management and treatment options.
According to the International Trade Administration, the proportion of the population older than 65 will rise from 29% to 40 % by 2060. As the elderly population expands, there is a corresponding surge in intracranial aneurysms, necessitating a heightened focus on healthcare strategies and interventions tailored to address this growing healthcare concern.
Endovascular treatments, such as coiling and stent-assisted coiling, have gained popularity in Japan due to their minimally invasive nature and favorable outcomes. These procedures involve the insertion of coils or stents into the aneurysm to promote clotting and reinforce the blood vessel walls, reducing the risk of rupture. Surgical options, such as clipping, remain an important component of intracranial aneurysm treatment, particularly for complex or large aneurysms that are not be suitable for endovascular interventions. Advances in surgical techniques and technologies have improved outcomes and reduced associated risks, contributing to the overall effectiveness of treatment strategies in Japan.
The COVID-19 pandemic has significantly impacted healthcare systems in Japan and has had implications for the management of intracranial aneurysms. The pandemic has led to disruptions in routine healthcare services, including elective procedures and non-urgent medical appointments, which have delayed diagnosis and treatment for some patients with intracranial aneurysms. Moreover, the increased strain on healthcare resources and prioritization of COVID-19-related care have affected the availability of specialized treatments and resources for intracranial aneurysms.
The Japanese intracranial aneurysm market is experiencing a notable surge in demand for advanced medical devices, driven by several key factors that underscore the evolving healthcare landscape in the country. Japan has witnessed a demographic shift towards an aging population, a demographic trend commonly associated with a higher incidence of neurological disorders, including intracranial aneurysms. The growing demand for advanced medical devices, particularly in the intracranial aneurysm market, has propelled Japan's medical devices industry.
According to the International Trade Administration, the medical devices industry in Japan achieved a significant milestone in 2021, reaching a total value of $40 billion. As Japan continues to prioritize advancements in healthcare technology, there has been a noticeable uptick in demand for cutting-edge medical devices, particularly in the intracranial aneurysm market.
Moreover, the Japanese healthcare system's emphasis on innovation and quality has created a conducive environment for adopting cutting-edge medical devices. The advancements in medical technology have led to the development of sophisticated devices that offer improved precision, safety, and efficacy in treating intracranial aneurysms. Endovascular techniques, including stents, coils, and flow diversion devices, have gained traction due to their minimally invasive nature and ability to achieve favorable clinical outcomes with reduced patient morbidity and mortality.
Additionally, the growing awareness among healthcare professionals and patients about the benefits of early detection and intervention for intracranial aneurysms has spurred the demand for diagnostic and therapeutic devices in Japan. Therefore, the convergence of Japan's aging population, emphasis on innovation in healthcare, and increased awareness of early intervention benefits have propelled significant growth in the demand for advanced medical devices in the intracranial aneurysm market.
The Japanese industry for surgical clipping in intracranial aneurysms has witnessed a notable surge in demand in recent years, driven by several key factors. One of the primary drivers of the increasing demand for surgical clipping in Japan is the growing awareness and diagnosis of intracranial aneurysms. Advancements in medical imaging technologies, improved access to healthcare services, and greater public awareness of neurological conditions have led to more frequent detection of intracranial aneurysms. As a result, there has been a corresponding rise in patients seeking treatment options, including surgical clipping.
Moreover, Japan's aging population demographics significantly drive the demand for surgical clipping procedures. With an increasing proportion of elderly individuals in the population, the prevalence of age-related risk factors for intracranial aneurysms, such as hypertension and atherosclerosis, has risen. Consequently, the number of patients requiring interventions to manage intracranial aneurysms, including surgical clipping, has also increased.
Additionally, advancements in surgical techniques and technologies have contributed to the growing popularity of surgical clipping as a treatment option in Japan. Surgeons can now access innovative tools and equipment that enable minimally invasive approaches, reducing surgical risks and patient recovery times. These advancements have made surgical clipping a more attractive option for patients and healthcare providers, further fueling its demand in the Japanese intracranial aneurysm market. Hence, the increasing awareness and advancements in surgical techniques and technologies are driving the notable surge in demand for surgical clipping in intracranial aneurysms within the Japanese healthcare industry.
The intracranial aneurysm market in Japan is a dynamic landscape shaped by advancements in medical technology, growing awareness, and the increasing prevalence of the condition. One notable player in Japan's intracranial aneurysm market is Kaneka Corporation. Kaneka is a diversified chemical company that has expanded into medical devices. The company offers various products for neurovascular interventions, including embolization coils and liquid embolisms used in treating intracranial aneurysms. Kaneka's focus on research and development ensures the continuous improvement of its products to meet the evolving needs of healthcare professionals and patients in Japan.
Another key contributor to the Japanese intracranial aneurysm market is Covidien, now part of Medtronic plc. Covidien was known for its extensive portfolio of medical devices, including those used in neurovascular interventions. The company's offerings included detachable coils and other embolization devices essential for treating intracranial aneurysms. Following its acquisition by Medtronic, Covidien's products continue to play a vital role in the Japanese intracranial aneurysm market, contributing to Medtronic's overall presence in the neurovascular space.
Furthermore, Japanese companies like Nipro Corporation contribute to the intracranial aneurysm market by providing essential medical devices and technologies. Nipro is known for its expertise in manufacturing medical equipment, including catheters and guidewires used in neurovascular interventions. By offering reliable and high-quality products, Nipro ensures the availability of essential tools for healthcare professionals performing endovascular procedures for intracranial aneurysms in Japan.
Additionally, Shimadzu Corporation, a prominent Japanese medical equipment manufacturer, offers imaging solutions that are integral to the diagnosis and treatment planning of intracranial aneurysms. Shimadzu's advanced imaging systems, including angiography and computed tomography (CT) scanners, provide healthcare professionals with detailed visualization of vascular structures, facilitating accurate diagnosis and precise treatment delivery for patients with intracranial aneurysms. Through their innovative products and technologies, these companies contribute to advancing intracranial aneurysm treatment, ultimately improving patient outcomes in Japan.
By End-use
By Type